Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2025 10:00 ET | Source: Dewpoint Therapeutics

FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer

Dewpoint's DPTX3186 receives FDA Orphan Drug Designation for gastric cancer - the first ever granted to a condensate-modulating therapeutic.